A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)

被引：0
|
作者：
Beeram, M.
Krop, I.
Modi, S.
Tolcher, A.
Rabbee, N.
Girish, S.
Tibbitts, J.
Holden, S.
Lutzker, S.
Burris, H.
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [41] T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
    Nicoletti, Roberta
    Lopez, Salvatore
    Bellone, Stefania
    Cocco, Emiliano
    Schwab, Carlton L.
    Black, Jonathan D.
    Centritto, Floriana
    Zhu, Liancheng
    Bonazzoli, Elena
    Buza, Natalia
    Hui, Pei
    Mezzanzanica, Delia
    Canevari, Silvana
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (01) : 29 - 38
  • [42] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [43] Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
    Dan Lu
    Sandhya Girish
    Yuying Gao
    Bei Wang
    Joo-Hee Yi
    Ellie Guardino
    Meghna Samant
    Melody Cobleigh
    Mothaffar Rimawi
    Pierfranco Conte
    Jin Yan Jin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 399 - 410
  • [44] Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer
    Myra F. Barginear
    Veena John
    Daniel R. Budman
    Molecular Medicine, 2012, 18 : 1473 - 1479
  • [45] Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer
    Barginear, Myra F.
    John, Veena
    Budman, Daniel R.
    MOLECULAR MEDICINE, 2012, 18 (11) : 1473 - 1479
  • [46] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
  • [47] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
    Sandhya Girish
    Manish Gupta
    Bei Wang
    Dan Lu
    Ian E. Krop
    Charles L. Vogel
    Howard A. Burris III
    Patricia M. LoRusso
    Joo-Hee Yi
    Ola Saad
    Barbara Tong
    Yu-Waye Chu
    Scott Holden
    Amita Joshi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1229 - 1240
  • [49] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [50] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
12345